Christopher F Giberson
Overview
Explore the profile of Christopher F Giberson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
99
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buchli R, VanGundy R, Giberson C, Hildebrand W
J Immunol Methods
. 2006 Jul;
314(1-2):38-53.
PMID: 16844138
There is currently a significant interest in the identification and validation of HLA-restricted CTL epitopes, which are thought to have important implications for the development of preventive and/or therapeutic applications...
2.
Buchli R, VanGundy R, Hickman-Miller H, Giberson C, Bardet W, Hildebrand W
Biochemistry
. 2005 Sep;
44(37):12491-507.
PMID: 16156661
Various approaches are currently proposed to successfully develop therapies for the prevention and treatment of infectious diseases and cancer. One of the most promising approaches is the development of vaccines...
3.
Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization
Buchli R, VanGundy R, Hickman-Miller H, Giberson C, Bardet W, Hildebrand W
Biochemistry
. 2004 Nov;
43(46):14852-63.
PMID: 15544356
Measuring the interaction of class I human leukocyte antigens (HLA) and their peptide epitopes acts as a guide for the development of vaccines, diagnostics, and immune-based therapies. Here, we report...
4.
Hickman H, Luis A, Buchli R, Few S, Sathiamurthy M, VanGundy R, et al.
J Immunol
. 2004 Feb;
172(5):2944-52.
PMID: 14978097
MHC class I molecules present host- and pathogen-derived peptides for immune surveillance. Much attention is given to the search for viral and tumor nonself peptide epitopes, yet the question remains,...